Zantac Lawyer #cities:t#, #stab:u#

Zantac was first released as a prescription drug in the U.S. in the early 1980s. Zantac and generic ranitidine were available in both prescription and over-the-counter form. This drug was originally developed and patented by the European pharmaceutical company Glaxo (n/k/a GlaxoSmithKline).

It was first approved and released as a prescription drug in Alameda in 1983. Glaxo invested millions in aggressively promoting the drug both to doctors and the general public.

People taking Zantac in Alameda, California might have unknowingly been ingesting incredibly high levels of NDMA into their system on a daily basis. Even the lower levels of NDMA found in the FDA testing are much more than the accepted safe daily limits for NDMA.

Given the known potential of NDMA to cause cancer in lab animals, Zantac users in Alameda may be at a significantly increased risk of developing various types of cancers.

Our Alameda Zantac lawsuit attorneys believe that these claims are the tip of a gigantic mass-tort iceberg. Zantac and its generic equivalents were widely used.

Literally millions of people in the U.S. used over-the-counter ranitidine medicine regularly for heartburn. This means that the size of potential claimants could be larger than any other defective drug cases.

As a result, a group of plaintiffs’ lawyers have filed a motion to consolidate all of the pending cases in federal courts to a single federal court.

As the motion points out, Zantac cases will “almost certainly dwarf the Valsartan litigation” (another NDMA MDL) because the “ubiquity of Zantac and the NDMA in Zantac is not an impurity that only recently made its way into the drug through shoddy manufacturing, but is instead, inherent to the drug’s molecular structure.” This motion was granted in February 2020 and MDL No. 2924 was formed.